Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a commercial-stage regenerative medicine company that entered the public markets in 2018 through a merger with Avista Healthcare Public Acquisition Corp, a blank-check vehicle sponsored by Avista Capital Partners. The company focuses on advanced wound care and surgical biologics, developing products for chronic and acute wound treatment. Organogenesis filed an 8-K current report with the SEC on June 16, 2026, under accession number 0001193125-26-272710, indicating a material event for investors and analysts to monitor. To access full filing details, sponsor history, and real-time SPAC analytics on Organogenesis Holdings and hundreds of other vehicles, sign up for a SpacDesk account today.